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Background: Anemia is a serious and highly prevalent co-morbidity in chronic heart failure 
(HF) patients. Its influence on health-related quality of life (HR-QoL) has rarely been studied, 
and no data is available regarding the role it plays in hospitalized HF patients.  
Methods: Baseline data from the COACH study (Coordinating study evaluating Outcomes of 
Advising and Counselling in Heart Failure) were used. HR-QoL was assessed by means of 
generic and disease-specific questionnaires. Analyses were performed using ANOVA and 
ANCOVA, with covariates of age, gender, eGFR, diabetes, and NYHA class.  
Results: In total, 1013 hospitalized patients with a mean age of 71 (SD 11) years were 
included; 70% of these patients had no anemia (n = 712), 14% had mild anemia (n = 141), 
and 16% had moderate-to-severe anemia (n = 160). Independent associations were found 
between anemia and physical functioning (p = 0.019), anemia and role limitations due to 
physical functioning (p = 0.002), anemia and general health (p = 0.024), and anemia and 
global well-being (p = 0.003). 
Conclusion: In addition to the burden of HF itself, anemia is an important factor which 
influences HR-QoL in hospitalized HF patients, and one that is most pronounced in the 
domain related to physical functioning and general health.  
 




Relief of symptoms and improvement in health-related quality of life (HR-QoL) are 
recognized as important objectives in the treatment of heart failure (HF) in international HF 
guidelines.1 However, despite the improvements in medical treatment resulting in 
prolonged survival and reduction of hospitalizations, HF patients still have an impaired HR-
QoL.2 HR-QoL in HF patients is seriously reduced compared to a normative population in the 
community,2 as well as compared to patients with other chronic diseases.3 Health status 
measurements such as HR-QoL quantify the extent to which a patient is impaired by the 
disease.4 A poor health status is a significant predictor of adverse prognosis in patients with 
chronic HF;5 therefore, reduction of HF symptoms and improvement in HR-QoL should be an 
important treatment goal for clinicians and other health-care professionals. In clinical trials, 
there is also an increasing interest in measuring patient-reported outcomes such as HR-QoL, 
since this has recently been recommended by the US Food and Drug Administration.6  
Anemia is a serious co-morbidity in patients with chronic HF and is prevalent in more 
than one-third of these patients.7 Anemia may cause a wide range of symptoms and 
impairments which correspond to the symptoms of HF such as dizziness, tachycardia, and 
dyspnea.1 The severity of the symptoms depends on the degree of anemia, other co-
morbidities, compensatory mechanisms, and the physiological status of the patient. 
Although the influence that anemia has on HF patients in terms of HR-QoL has rarely been 
studied, intervention trials to correct anemia have already used HR-QoL as an effect 
parameter.8-11 To date, only one study has examined the direct relationship between HR-
QoL and anemia in a population of 826 HF-stable outpatients with a mean age of 64 years.12 
To our knowledge, there are no data available regarding the role it plays in hospitalized HF 
patients. The aim of the present study is to further assess the relationship between HR-QoL 
and anemia in hospitalized HF patients. The following research questions will be addressed 
in this study: Is there an independent association between HR-QoL and anemia in 











Baseline data from the COACH study (Coordinating study evaluating Outcomes of Advising 
and Counselling in Heart Failure) were used for this study. The COACH study was a 
multicenter, randomized controlled trial designed to compare the effects of basic support 
and intensive support in HF patients, using a control group receiving usual care.13 Details on 
the design of the COACH study have been published elsewhere.14 In short, 1023 patients 
from seventeen hospitals in the Netherlands were included in the study from October 2002 
to February 2005. Patients were included during admission to the hospital with symptoms 
of HF and NYHA II-IV. The HF diagnosis was made on the basis of a combination of typical 
signs and symptoms, for which hospitalization was considered necessary, including the need 
for intravenously administered medication. Other enrolment criteria were 18 years of age or 
older and having evidence of structural underlying heart disease. Patients with impaired left 
ventricular ejection fraction (LVEF) and those with preserved LVEF could also be included. 
Patients were excluded if they were unable to complete data collection forms, had 
undergone invasive intervention within the last 6 months or had one planned for the 
ensuing 3 months, or were in ongoing evaluation for heart transplantation. During 
hospitalization, patients were randomized to one of the following groups: basic support, 
intensive support, or control group. Our investigation conforms to the principles outlined in 
the Declaration of Helsinki. The medical ethics committee approved the study protocol, and 
all the enrolled patients provided their written informed consent. The authors of this 
manuscript have certified that they are in compliance with the Principles of Ethical 
Publishing in the International Journal of Cardiology.15 
Measurements 
HR-QoL 
HR-QoL was assessed using three instruments: two generic (RAND 36-item Health Survey 1.0 
and Cantril’s Ladder of Life) and one disease-specific instrument, the Minnesota Living with 
Heart Failure Questionnaire (MLHFQ). In general, disease-specific questionnaires are used 
for patients with a specific health condition, while generic instruments are used in patients 
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with various health conditions.16,17 Generic instruments are not affected in terms of their 
validity, reliability, and responsiveness if a patient has co-morbidities which manifest similar 
effects as a primary disease.18 Generic HR-QoL can be influenced by nonmedical phenomena 
such as employment and family relationships.16 Therefore we used a global QoL instrument 
(Cantril’s Ladder of Life) in addition to a generic HR-QoL instrument (RAND 36-item Health 
Survey 1.0).19 
The RAND 36-item Health Survey 1.0 consists of eight domains: physical functioning, 
social functioning, role limitations (physical problems), role limitations (emotional 
problems), mental health, vitality, bodily pain, and general health perception. For each 
domain, scores range from 0 (poorest health) to 100 (best health). Higher scores reflect 
better HR-QoL. The RAND 36-item Health Survey 1.0 includes the same items as those in the 
SF-36; however, the scoring algorithm is different compared to the SF-36. Therefore the 
RAND 36-item Health Survey 1.0 does not have component summary scores.20 Moreover, 
unlike the SF-36, the RAND 36-item Health Survey 1.0 does not have norm scores available 
for comparison. It has, however, previously been used in a Dutch population and was found 
to have good psychometric properties.21,22 Generally speaking, a difference of 5 points on 
the domain scores is considered to be clinically relevant. The Cantril’s Ladder of Life assesses 
a patient’s global well-being on a scale between zero, indicating the poorest, and 10, 
indicating the best well-being, and has been used in HF research before.23,24 The MLHFQ is a 
widely used disease-specific questionnaire in HF research19,25 that has good psychometric 
properties.25 The MLHFQ has a total score ranging between zero and a maximum of 105, 
and consists of two domains, a physical component and an emotional component with, 
respectively, 40 and 25 as maximum possible scores. Lower scores on the MLHFQ reflect 
better HR-QoL.26  
Clinical measurements 
Anemia was defined for adult men and women according to the definition of the World 
Health Organization (WHO) as a hemoglobin (Hb) level being, either below 8.0 mmol/L or 
below 7.5 mmol/L, respectively.27 To examine the association between the severity of the 
anemia and HR-QoL, subgroups of anemic patients were created. To create suitable groups 
for comparison in the present study, we combined data from patients with severe anemia 
and moderate anemia into one group, denoted as the moderate-to-severe anemia group. 
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Mild anemia was defined for male and female patients as an Hb level below 8.0 mmol/L and 
7.5 mmol/L, respectively. Moderate-to-severe anemia was defined as an Hb level lower than 
7.5 mmol/L in male patients, and an Hb level lower than 6.8 mmol/L in female patients.28 
Demographic and clinical data were collected from patient interviews and from 
patients’ medical charts at baseline, except for LVEF, which was measured close to 
admission and at a maximum of one year before or after.  
Statistical analysis 
Patient characteristics and clinical and HR-QoL outcomes were described using means (± SD) 
for continuous variables and using percentages and numbers for categorical variables. 
Continuous variables were tested using one-way analysis of variance (ANOVA), and 
categorical variables using the Chi square test. Welch F tests were performed if the 
homogeneity of variance was violated according to Levine’s test. Analysis of covariance 
(ANCOVA) was used to assess an independent association between anemia and HR-QoL, 
along with a correction for variables known to influence Hb levels and HR-QoL such as age,29 
gender,27,30 diabetes,2 eGFR,31 and NYHA classification.32 Severity of anemia (no anemia, 
mild anemia, and moderate-to-severe anemia) was the factor variable, while HR-QoL was 
the dependent variable. Comparisons between the different anemia groups were performed 
using post hoc analyses with correction for multiple comparisons using Bonferroni. A 
regression analysis was performed to determine the contribution of anemia to the physical 




Patients were included in the current study if baseline levels of Hb were available; as a result 
of this, 1013 patients were included. Patients had a mean age of 71 (±11) years, while 62% 
of the patients were male. Most patients were classified as NYHA III-IV upon admission; 
while on discharge most were NYHA class II (51%) or III (46%). Co-morbidities were present: 
28% of the patients had diabetes, 26% chronic obstructive pulmonary disease (COPD), 10% 
have had a stroke and 43% had hypertension. (Table 1). On the basis of the WHO definition, 
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30% were anemic, 14% had mild anemia, and 16% had moderate-to-severe anemia. 
Baseline characteristics differed significantly across the anemic groups. The severity of 
anemia was associated with higher age (p = 0.001), higher LVEF (p = 0.011), lower eGFR 
levels (p < 0.001), male gender (p = 0.019), the use of angiotensin-converting enzyme or 
angiotensin II inhibitor (p < 0.001), higher prevalence of the co-morbidities of diabetes (p < 
0.001), and stroke (p = 0.001). A non-significant association was found for NYHA 
classification and severity of anemia (Table 1).  
Association between HR-QoL and anemia 
For the RAND 36-item Health Survey 1.0, univariate analyses (Table 2) indicated significant 
associations between anemia and the five domains of the survey: physical functioning (p < 
0.001), role limitation physical (p < 0.001), role limitation emotional (p = 0.028), bodily pain 
(p = 0.038), and general health (p = 0.002). Three domains remained significant in the 
multivariate analyses: physical functioning (p = 0.019), role limitation physical (p = 0.002), 
and general health (p = 0.024). In terms of the contribution of anemia to HR-QoL for the 
domains physical functioning and role limitation physical, anemia showed for physical 
functioning the lowest standardized beta coefficient (-0.076) when compared to NYHA 
classification (-0.29), gender (-0.11), renal function (0.10), age (-0.09) and the presence of 
diabetes (-0.09). For role limitation physical these figures were less attenuated; anemia (-
0.11), NYHA classification (-0.17), gender (-0.03), renal function (0.001), age (0.04) and the 
presence of diabetes (-0.04). Post hoc analyses (Figure 1) indicated an independent 
significant association between non-anemic versus mild anemic patients (p = 0.019), and 
between non-anemic versus moderate-to-severe anemic patients (p = 0.026) in the domain 
of role limitation physical. For the domain of general health, significant associations were 
found between non-anemic versus moderate-to-severe anemic patients (p = 0.040). A non-
significant association between non-anemic versus mild anemic patients for the domain of 
physical functioning (p = 0.059) was found.  
Using Cantril’s Ladder of Life, a significant univariate association was found between 
anemia and global well-being (p = 0.003). This association remained significant in the 
multivariate analyses (p = 0.003), specifically between non-anemic versus moderate-to-
severe anemic patients (p = 0.002) (Figure 2). 
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For MLHFQ, neither the total score, nor the physical and emotional components 
were associated with anemia.  
Discussion 
This is the first study to report on a significant independent association between HR-QoL 
and anemia in patients hospitalized for HF. The current study provides further support for 
the relationship between HR-QoL and anemia in HF patients. Although the association 
between HR-QoL and anemia was reported in other diseases,33,34 in HF patients only one 
study reported on this direct relationship in a stable outpatient population with a mean age 
of 64 years, independent of functional class, ejection fraction, gender, and age.12 The 
present study adds to this by showing that this independent association is also present in 
hospitalized HF patients. In these patients, hospitalized because of severe HF symptoms 
which often result in a severely impaired HR-QoL,2 we still found an independent association 
between anemia and HR-QoL.  
The present study is also the first to use both generic and disease-specific 
questionnaires to assess the association between HR-QoL and anemia. In using those 
questionnaires, we considered HR-QoL in patients in terms of its specific relationship to 
their HF and in terms of a general, broader concept, unrelated to any specific disease. 
Independent associations were only found between generic HR-QoL and anemia, which 
would indicate that HF patients with anemia have additional difficulties on top of their HF 
symptoms; these difficulties cannot be detected by disease-specific questionnaires alone. 
Another explanation could be that the MLHFQ was not sensitive enough in this population 
because of the small sample sizes in the anemia groups.35 Moreover, the MLHFQ is not 
specifically designed for use in acute HF, though it is very frequently used in HF trials to 
study patients with chronic HF. The most pronounced associations between HR-QoL and 
anemia were found in the domains of physical functioning and limitations due to physical 
functioning. Both domains reflect limitations in terms of performing daily activities, such as 
climbing stairs, bathing or dressing, or carrying groceries, which are due to physical health 
problems.21,22 These daily activities are particularly important for older adults in maintaining 
or increasing their quality of life.36 Moreover, physical activity in terms of exercise and the 
performance of daily activities is recommended for HF patients;1,37 this is an established life-
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style recommendation37,38 for improving HR-QoL.37 Furthermore, independent associations 
were found for general health and global well-being, which reflects the fact that HF patients 
with anemia have a lower opinion of their health than do HF patients without anemia. This 
independent association remains if we correct for other co-morbidities such as stroke and 
hypertension. This is in accord with the literature: HR-QoL declines with any increasing 
burden of co-morbidity in cardiac patients.2,39 In general, older people with anemia 
experience a decline in functional status and physical strength as compared to non-anemic 
elderly.40 In contrast to the study by Thein and colleagues, in which anemia was associated 
with depressive symptoms,40 we found no relationship between anemia and the mental 
aspects of HR-QoL. We also did not find any significant association between anemia and the 
HR-QoL domain of vitality, which reflects feelings of energy and tiredness.21,22 Tiredness and 
lack of energy are symptoms of both anemia and HF, which may explain why no significant 
association was found for this domain.  
In addition to the substantial risk of adverse events and death in anemic HF 
patients,41 these patients also seem at risk of a decline in their HR-QoL. Although our study 
had a cross-sectional design which precludes conclusions as to causality, our findings 
suggest that specific treatment for anemia should be considered because effective 
treatment may improve HR-QoL in these HF patients. Although the best treatment for 
anemia in HF patients is still open to debate,42 the first randomized clinical trials suggest 
that treating anemia improves exercise tolerance, reduces symptoms, and improves HR-
QoL.11,41  
One limitation of our study is that we performed post hoc analyses that assessed the 
association between HR-QoL and anemia using baseline data from the COACH study; this 
study was originally designed to determine the effectiveness of two interventions (basic 
support versus intensive support) as compared to “care as usual” in HF patients with the 
following primary endpoint: the composite of HF hospitalization or death from any cause 
and the number of unfavorable days. Another limitation is that data from clinical trials are 
known to present difficulties in terms of generalizability. However, we believe that this is a 
sample that reasonably represents the clinical sample of HF patients in general2 in view of 
the mean age of 71 years and the distribution of male patients in the study population.  
 




The most important finding of this study is that HR-QoL has been shown to be 
independently associated with anemia in hospitalized HF patients in terms of global well-
being, general health, physical functioning, and limitations due to physical functioning. HR-
QoL was found to be particularly lower in patients with severe-to-moderate anemia. The 
association between HR-QoL and (severe) anemia in HF patients is remarkable, and might 
serve as a possible mechanism for improving HR-QoL in anemic HF patients. More research 
into this association is needed.  
 




Figure 1: Post hoc analyses of health-related quality of life measured using the RAND 36-item Health Survey in 
heart failure patients without anemia, and in those with mild and moderate-to-severe anemia. Lines indicate a 
significant difference (p < 0.05) between the group with correction for age, gender, NYHA classification, 
diabetes, and eGFR level. (PF = physical functioning; SF = social functioning; RF = role limitations due to 
physical functioning; RE = role limitations due to emotional functioning; MH = mental health; VT = vitality; BP = 
bodily pain, GHP = general health perception) 
 
Figure 2: Post hoc analyses of health-related quality of life measured using Cantril’s Ladder of Life in heart 
failure patients without anemia, and in those with mild, moderate, and severe anemia. Line indicates a 
significant difference (p < 0.05) between the group with correction for age, gender, NYHA classification, 
diabetes, and eGFR level. 
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Table 1. Characteristics of the study population  
 All patients  
(n = 1013) 
Non-anemic 
(n=712) 
Mild-anemic   
(n= 141) 
Moderate-to-severe 
anemic (n = 160) 
P-
value 
Demographics       
Age (years) 71 (±11) 70 (±11) 72 (±11) 73 (±11) 0.001 
Gender (male) 62% (632) 62% (439) 56% (79) 71% (114) 0.019 
Clinical characteristics      
NYHA:       
II 51% (506) 53% (369) 46% (65) 46% (72)  
III 46% (458) 44% (312) 51% (72) 48% (74) 0.088 
IV 3% (34) 3% (21) 2% (3) 6% (10)  
LVEF % 34 (±14) 33 (±14) 36 (±15) 36 (±15) 0.011 
eGFR (ml/min*1.73m2) 56 (±20) 59 (±19) 50 (±21) 48 (±23) <0.001 
Hemoglobin (mmol/l) 8.3 (±1.1) 8.9 (±0.8) 7.5 (±0.3) 6.6 (±0.5) <0.001 
BNP (µg/L) 680 (±729) 623 (±675) 734 (±796) 887 (±856) 0.001 
Discharge medication      
ACE/ARB 83% (838) 87% (617) 76% (107) 71% (114) <0.001 
Β- blockers 66% (670) 67% (479) 68% (96) 59% (95) 0.141 
Diuretics 96% (970) 96% (682) 97% (137) 94% (151) 0.487 
Medical history 28% (285) 25% (175) 31% (44) 41% (66) <0.001 
Diabetes 26% (267) 25% (176) 29% (41) 31% (50) 0.174 
COPD 10% (105) 8% (60) 11% (15) 19% (30) 0.001 
Stroke 43% (436) 42% (299) 55% (78) 37% (59) 0.003 
Hypertension 28% (285) 25% (175) 31% (44) 41% (66) <0.001 
Note: 
Mean (±SD), percentage (number) 
P: between anemic groups; Hb: hemoglobin; Non-anemic female: Hb ≥ 7.5 mmol/L; Non-anemic male: Hb ≥ 8.0 
mmol/L; Mild anemic female: 6.8 mmol/L ≤ Hb < 7.5 mmol/L; Mild anemic male: 7.5 mmol/L ≤ Hb < 8.0 
mmol/l; Moderate-to-severe anemic female: Hb < 6.8 mmol/L; Moderate-to-severe anemic male: Hb < 7.5 
mmol/L; NYHA = New York Heart Association; LVEF: Left Ventricular Ejection Fraction; eGFR: estimated 
glomular filtration rate; BNP: brain natriuretic peptide; ACE/ARB: angiotensin-converting enzyme/angiotensin 
II inhibitor; COPD: Chronic Obstructive Pulmonary Disease 
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(n = 712) 
Mild anemic 
(n = 141) 
Moderate-to-severe 
anemic (n = 160) 
*P **P 
RAND 36- item Health Survey      
Physical functioning 37 (±27) 29 (±23) 29 (±23) <0.001 0.019 
Social functioning 54 (±31) 53 (±31) 48 (±30) 0.056  
Role limitation physical 21 (±35) 11 (±27) 12 (±28) <0.001 0.002 
Role limitation emotional 54 (±45) 48 (±45) 43 (±45) 0.028 0.146 
Mental health 66 (±23) 65 (±20) 65 (±24) 0.949  
Vitality 40 (±23) 40 (±21) 37 (±22) 0.319  
Bodily pain 66 (±33) 61 (±31) 59 (±34) 0.038 0.142 
General health 45 (±19) 41 (±17) 39 (±18) 0.002 0.024 
MLHFQ      
Total  43 (±22) 46 (±20) 45 (±21) 0.104  
Physical component 22 (±10) 24 (±9) 24 (±9) 0.138  
Emotional component 7 (±6) 7 (±6) 7 (±6) 0.989  
Ladder of life 6.4 (±1.9) 6.2 (±1.8) 5.8 (±2.0) 0.003 0.003 
Note: 
Mean (±SD); Hb: hemoglobin; Non-anemic female: Hb ≥ 7.5 mmol/L; Non-anemic male Hb ≥ 8.0 mmol/L; Mild 
anemic female: 6.8 mmol/L ≤ Hb < 7.5 mmol/L; Mild anemic male: 7.5 mmol/L ≤ Hb < 8.0 mmol/l; Moderate-
to-severe anemic female: Hb < 6.8 mmol/L; Moderate-to-severe anemic male: Hb < 7.5 mmol/L 
P* univariate association between HR-QoL and anemia severity 
P** multivariate association between HR-QoL and anemia severity with covariates age, gender, NYHA 
classification, diabetes, and eGFR level 
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